Anti-doxorubicin2929 Balsari AL, Morelli D, Ménard S, Veronesi U, Colnaghi MI. Protection against doxorubicin-induced alopecia in rats by liposome-entrapped monoclonal antibodies. FASEB J. 1994;8:226-30.
|
Topical minoxidil2323 Duvic M, Lemak NA, Valero V, Hymes SR, Farmer KL, Hortobagyi GN, et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996;35:74-8.
|
AS1013030 Sredni B, Xu RH, Albeck M, Gafter U, Gal R, Shani A, et al. The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models. Int J Cancer. 1996;65:97-103.
|
Topical epinephrine and norepinephrine3131 Soref CM, Fahl WE. A new strategy to prevent chemotherapy and radiotherapy-induced alopecia using topically applied vasoconstrictor. Int J Cancer. 2015;136:195-203.
|
Parathyroid hormone receptor (PPR) ligands3232 Skrok A, Bednarczuk T, Skwarek A, Popow M, Rudnicka L, Olszewska M. The effect of parathyroid hormones on hair follicle physiology: implications for treatment of chemotherapy-induced alopecia. Ski Pharmacol Physiol. 2015;28:213-25.
|
Scalp cooling99 Nangia J, Wang T, Osborne C, Niravath P, Otte K, Papish S, et al. Effect of a scalp cooling device on alopecia inwomen undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial. JAMA. 2017;317:596-605.,3333 van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, Nortier JW, Coebergh JW, Breed WP. Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients – results of the Dutch Scalp Cooling Registry. Acta Oncol. 2012;51:497-504.,3434 Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA. 2017;317:606-14.
|
Topical n-acetyl cysteine3535 Jiménez JJ, Huang HS, Yunis AA. Treatment with ImuVert/N-acetylcysteine protects rats from cyclophosphamide/cytarabine-induced alopecia. Cancer Invest. 1992;10:271-6.
|
Scalp tourniquet3636 Maxwell MB. Scalp tourniquets for chemotherapy-induced alopecia. Am J Nurs. 1980;80:900-3.
|
|
Topical antioxidants (resveratrol, aminothiol)3131 Soref CM, Fahl WE. A new strategy to prevent chemotherapy and radiotherapy-induced alopecia using topically applied vasoconstrictor. Int J Cancer. 2015;136:195-203.
|
Topical calcitriol3737 Paus R, Schilli MB, Handjiski B, Menrad A, Henz BM, Plonka P. Topical calcitriol enhances normal hair regrowth but does not prevent chemotherapy-induced alopecia in mice. Cancer Res. 1996;56:4438-43.
|
|
Topical cyclosporine A3838 Hussein A, Stuart A, Peters WP. Protection against chemotherapy-induced alopecia by cyclosporin a in the newborn rat animal model. Dermatology. 1995;190:192-6.
|
DHL-HisZnNA3939 Sagawa N, Ohno S, Hiratsuka T, Kondo N, Iwata H, Bando H, et al. The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial. Breast Cancer Res Treat. 2019;176:625-30.
|
|
Immunomodulators (Il-1,4040 Jimenez JJ, Yunis AA. Protection from 1-beta-D-arabinofuranosylcytosine-induced alopecia by epidermal growth factor and fibroblast growth factor in the rat model. Cancer Res. 1992;52:413-5. imuvert4141 Houssein AM. Chemotherapy-induced alopecia: new developments. South Med J. 1993;86:489-96.) |
|
|
Acid FGF, EGF4040 Jimenez JJ, Yunis AA. Protection from 1-beta-D-arabinofuranosylcytosine-induced alopecia by epidermal growth factor and fibroblast growth factor in the rat model. Cancer Res. 1992;52:413-5.
|
|
|
CDK2 inhibitors4242 Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002;23:417-25.
|
|
|
Caspase-3 inhibitors4343 Porter AG, Jänicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999;6:99-104.
|
|
|
Multi-target iron chelator M304444 Lim YC, Kim H, Lim SM, Kim JS. Genetic analysis of a noval antioxidant multi-target iron chelator, M30 protecting against chemotherapy-induced alopecia in mice. BMC Cancer. 2019;19:149.
|
|
|